Equity awards granted to Sagimet (SGMT) Chief Legal & Admin. Officer

Rhea-AI Filing Summary

Rozek Elizabeth reported acquisition or exercise transactions in this Form 4 filing.

Sagimet Biosciences Inc. reported that Chief Legal & Administrative Officer Elizabeth Rozek received new equity awards. She was granted an option to buy 88,000 shares of Series A Common Stock, vesting in 48 equal monthly installments starting February 19, 2026. She was also awarded 44,000 restricted stock units, each representing one share of Series A Common Stock, vesting in four equal annual installments from the same date, contingent on continued service.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Rozek Elizabeth

(Last) (First) (Middle)

SAGIMET BIOSCIENCES INC.

155 BOVET ROAD, SUITE 303

(Street)

SAN MATEO CA 94402

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Sagimet Biosciences Inc. [ SGMT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Legal & Admin. Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/19/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Series A Common Stock	02/19/2026		A		44,000(1)	A	$0.00	234,959	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$5.38	02/19/2026		A		88,000		(2)	02/18/2036	Series A Common Stock	88,000	$0.00	88,000	D

Explanation of Responses:

1. Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Series A Common Stock upon vesting and settlement. The RSUs shall vest over four equal annual installments following February 19, 2026, subject to the Reporting Person's continued service on each such vesting date.

2. The shares underlying this option shall vest and become exercisable over forty-eight equal monthly installments following February 19, 2026, subject to the Reporting Person's continued service on each such vesting date.

	/s/ Elizabeth Rozek	02/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider equity awards did Sagimet Biosciences (SGMT) report for Elizabeth Rozek?

Sagimet Biosciences reported that Chief Legal & Administrative Officer Elizabeth Rozek received two equity awards: a stock option for 88,000 shares and 44,000 restricted stock units. Both awards relate to the company’s Series A Common Stock and are contingent on her continued service.

How many stock options did Elizabeth Rozek acquire in the latest Sagimet (SGMT) Form 4?

Elizabeth Rozek acquired a stock option covering 88,000 shares of Sagimet’s Series A Common Stock. These options vest and become exercisable in 48 equal monthly installments beginning February 19, 2026, provided she continues to serve the company on each vesting date.

What are the vesting terms for Elizabeth Rozek’s restricted stock units at Sagimet (SGMT)?

Rozek’s 44,000 restricted stock units vest in four equal annual installments following February 19, 2026. Each RSU represents a contingent right to receive one share of Series A Common Stock, subject to her continued service on each applicable vesting date.

Are Elizabeth Rozek’s new Sagimet (SGMT) equity awards direct holdings?

Yes. The Form 4 identifies both the 88,000-share option and the 44,000-share restricted stock unit award as directly held by Elizabeth Rozek. The filing does not attribute these awards to any separate entity or indirect ownership structure.

Does Elizabeth Rozek’s Sagimet (SGMT) Form 4 involve any stock sales?

No. The Form 4 only shows acquisitions coded as grants or awards, with no reported sales. Transactions are classified under code “A” for grant, covering stock options and restricted stock units tied to future vesting conditions, rather than open-market buying or selling.

When does vesting begin for the new Sagimet (SGMT) equity awards to Elizabeth Rozek?

Vesting for both the stock options and restricted stock units begins after February 19, 2026. The options vest monthly over 48 installments, while the RSUs vest annually over four equal installments, each conditioned on her continued service with Sagimet Biosciences.